Clinical Trials Browser

Phase 2 × Has results × PM 01183 × Clear all

NCT05126433 2025-02-28

JAZZ EMERGE201

Phase 2 Terminated

47 enrolled 16 charts

Neoplasm Metastasis

NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Phase 2 Completed

345 enrolled 34 charts 1 FDA

Other solid neoplasm

Advanced Solid Tumors

NCT02448537 2021-03-03

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

Phase 2 Completed

42 enrolled 11 charts

Sarcoma

NCT01525589 2020-09-25

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Phase 2 Completed

111 enrolled 31 charts

Breast Neoplasms

NCT02451007 2019-11-19

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

Phase 2 Completed

39 enrolled 11 charts

Other solid neoplasm

Solid Tumors

NCT01951157 2019-09-24

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 2 Completed

69 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung